Table 3.
Biodistributions of new cross-bridged uPAR PET tracersa .
| 64Cu-CB-TE2A-AE105 | 64Cu-CB-TE2A-PA-AE105 | |||
|---|---|---|---|---|
| Organ | 1 h (%ID/g) | 22 hrs (%ID/g) | 1 h (%ID/g) | 22 hrs (%ID/g) |
| Blood | 1.4 ± 0.2 | 0.4 ± 0.1 | 2.0 ± 0.3 | 0.2 ± 0.1 |
| Liver | 11.2 ± 1.2 | 3.6 ± 0.4 | 4.8 ± 0.7 | 1.6 ± 0.1 |
| Kidney | 15.0 ± 1.0 | 5.2 ± 1.4 | 14.0 ± 1.6 | 4.8 ± 0.7 |
| Lung | 5.5 ± 1.4 | 2.9 ± 0.4 | 4.3 ± 0.7 | 2.0 ± 0.8 |
| Spleen | 6.2 ± 1.2 | 2.9 ± 0.7 | 2.8 ± 0.3 | 2.7 ± 0.3 |
| Heart | 1.2 ± 0.1 | 1.0 ± 0.2 | 1.1 ± 0.1 | 0.6 ± 0.1 |
| Stomach | 1.7 ± 0.6 | 1.1 ± 0.4 | 1.3 ± 0.8 | 0.7 ± 0.1 |
| Intestine | 4.3 ± 1.1 | 2.1 ± 0.4 | 3.7 ± 0.8 | 1.3 ± 0.1 |
| Muscle | 0.3 ± 0.1 | 0.2 ± 0.1 | 0.5 ± 0.2 | 0.1 ± 0.1 |
| Bone | 1.1 ± 0.4 | 0.8 ± 0.3 | 0.9 ± 0.1 | 0.9 ± 0.3 |
| Brain | 0.2 ± 0.1 | 0.1 ± 0.1 | 0.1 ± 0.1 | 0.1 ± 0.1 |
| Tumor | 3.6 ± 1.0 | 2.1 ± 0.3 | 3.0 ± 0.9 | 2.0 ± 0.3 |
| Tumor-to-nontumor ratios | ||||
| Tumor-to-blood | 2.6 ± 0.5 | 5.2 ± 0.5 | 1.5 ± 0.4 | 9.3 ± 1.7 |
| Tumor-to-liver | 0.3 ± 0.1 | 0.6 ± 0.1 | 0.7 ± 0.3 | 1.3 ± 0.2 |
| Tumor-to-kidney | 0.2 ± 0.1 | 0.4 ± 0.1 | 0.2 ± 0.1 | 0.5 ± 0.1 |
| Tumor-to-intestine | 0.8 ± 0.1 | 1.0 ± 0.2 | 0.9 ± 0.3 | 1.6 ± 0.2 |
| Tumor-to-muscle | 1.4 ± 0.2 | 17.5 ± 8.0 | 7.5 ± 5.0 | 22.2 ± 15.3 |
aThe biodistributions profiles and tumor to non-tumor ratios for 64Cu-CB-TE2A-AE105 and 64Cu-CB-TE2A-PA-AE105 were established in nude mice bearing U87MG xenografts by gamma counting of resected organs.